Overview

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Status:
RECRUITING

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

orforglipron